<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Financial Stability on FinanClub</title>
    <link>https://finan.club/tags/financial-stability/</link>
    <description>Recent content in Financial Stability on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 06 Apr 2024 09:05:04 +0000</lastBuildDate><atom:link href="https://finan.club/tags/financial-stability/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>ROIV</title>
      <link>https://finan.club/us/roiv/</link>
      <pubDate>Sat, 06 Apr 2024 09:05:04 +0000</pubDate>
      
      <guid>https://finan.club/us/roiv/</guid>
      <description>score:-124
Chances: Roivant Sciences Ltd. has shown significant growth and positive results in its product portfolio, indicating potential for future success in the biopharmaceutical industry. The approval of a $1.5 billion share repurchase program and the successful sale of Telavant to Roche for $7.</description>
    </item>
    
  </channel>
</rss>
